The eval of the event is based on mfg and qc procedures and history of the device related to this event.
Based on the commercial experience, the frequency of reported collagen insertions and thrombus is lower than that observed in the clinical studies performed in support of the pre-market approval of the product.
Based on the experience with vasoseal, co believes that the risk of collagen insertion can be minimized by explicity following the technique discussed in the vasoseal instructions for use regarding the initial puncture and placement of the vasoseal components.
|